Paradigm Biopharmaceuticals Management
Management criteria checks 2/4
Paradigm Biopharmaceuticals' CEO is Paul Rennie, appointed in Jan 2014, has a tenure of 10.25 years. total yearly compensation is A$1.95M, comprised of 30.9% salary and 69.1% bonuses, including company stock and options. directly owns 2.65% of the company’s shares, worth $1.72M. The average tenure of the management team and the board of directors is 3.7 years and 3.5 years respectively.
Key information
Paul Rennie
Chief executive officer
AU$1.9m
Total compensation
| CEO salary percentage | 30.9% |
| CEO tenure | 10.3yrs |
| CEO ownership | 2.6% |
| Management average tenure | 3.7yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$69m |
| Sep 30 2023 | n/a | n/a | -AU$60m |
| Jun 30 2023 | AU$2m | AU$602k | -AU$52m |
| Mar 31 2023 | n/a | n/a | -AU$48m |
| Dec 31 2022 | n/a | n/a | -AU$44m |
| Sep 30 2022 | n/a | n/a | -AU$42m |
| Jun 30 2022 | AU$1m | AU$219k | -AU$39m |
| Mar 31 2022 | n/a | n/a | -AU$40m |
| Dec 31 2021 | n/a | n/a | -AU$41m |
| Sep 30 2021 | n/a | n/a | -AU$37m |
| Jun 30 2021 | AU$1m | AU$510k | -AU$34m |
| Mar 31 2021 | n/a | n/a | -AU$31m |
| Dec 31 2020 | n/a | n/a | -AU$28m |
| Sep 30 2020 | n/a | n/a | -AU$20m |
| Jun 30 2020 | AU$632k | AU$462k | -AU$12m |
| Mar 31 2020 | n/a | n/a | -AU$14m |
| Dec 31 2019 | n/a | n/a | -AU$16m |
| Sep 30 2019 | n/a | n/a | -AU$16m |
| Jun 30 2019 | AU$1m | AU$420k | -AU$16m |
| Mar 31 2019 | n/a | n/a | -AU$11m |
| Dec 31 2018 | n/a | n/a | -AU$7m |
| Sep 30 2018 | n/a | n/a | -AU$7m |
| Jun 30 2018 | AU$573k | AU$380k | -AU$6m |
| Mar 31 2018 | n/a | n/a | -AU$6m |
| Dec 31 2017 | n/a | n/a | -AU$5m |
| Sep 30 2017 | n/a | n/a | -AU$5m |
| Jun 30 2017 | AU$517k | AU$350k | -AU$4m |
Compensation vs Market: Paul's total compensation ($USD1.27M) is above average for companies of similar size in the US market ($USD667.11K).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
CEO
Paul Rennie (64 yo)
10.3yrs
Tenure
AU$1,947,027
Compensation
Mr. Paul John Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, served as Independent Non-Executive Chairman at NeuroScientific Biopharmaceuticals Limited since June 21, 2021 until November 23, 2022, was it...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.3yrs | AU$1.95m | 2.65% A$ 1.7m | |
| Chief Medical Officer and Executive Director | 1.8yrs | AU$1.51m | 0.31% A$ 202.8k | |
| Interim Company Secretary & Interim CFO | 1.7yrs | no data | no data | |
| Chief Scientific Officer | 8.6yrs | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Global Head of Drug Safety & MPS | 3.8yrs | no data | no data | |
| Commercial Head | 3.5yrs | no data | no data | |
| Global Head of Regulatory Affairs | no data | no data | no data | |
| Global Clinical Head of OA | no data | no data | no data |
3.7yrs
Average Tenure
Experienced Management: PBIG.F's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.9yrs | AU$1.95m | 2.65% A$ 1.7m | |
| Chief Medical Officer and Executive Director | 3.8yrs | AU$1.51m | 0.31% A$ 202.8k | |
| Independent & Non-Executive Director | 3.3yrs | AU$88.40k | no data | |
| Independent Non-Executive Director | 3.2yrs | AU$88.40k | 0.0032% A$ 2.1k |
3.5yrs
Average Tenure
64yo
Average Age
Experienced Board: PBIG.F's board of directors are considered experienced (3.5 years average tenure).